Japan Kaketsuken Obtains Approval For Hep-B Vaccine, HB Immunoglobulin
This article was originally published in PharmAsia News
Executive Summary
Kaketsukan obtained approval for the use of their Bimmugen hepatitis B vaccine and anti-HB immunoglobulin Hepatothera 200/mL injection for newborns for prevention of mother-to-child transmission of hepatitis B, the company announced on March 18.